AbCellera Biologics Inc. (ABCL) key performance indicators and operating metrics (9 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Molecules in the clinic | 12.00 | FY2026-Q2 |
| Partner-led programs with downstream participation | 35.00 | FY2026-Q2 |
| Partner-initiated program starts with downstream participation | 103.00 | FY2025-Q3 |
| Cumulative partner-initiated program starts with downstream participation | 102.00 | FY2025-Q2 |
| Available liquidity | 675M | FY2026-Q2 |
| Research fees revenue | 8.12M | FY2026-Q1 |
| Total available government funding | 110M | FY2026-Q2 |
| Revenue from licensing and royalty payments | 149K | FY2026-Q2 |
| Discovery programs in the pipeline | 20.00 | FY2025-Q2 |
Back to ABCL overview · ABCL earnings · ABCL holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.